IMBiotechnologies produces Ekboi Embolization Microspheres, a biodegradable embolic agent that is detectable by ultrasound. It is approved in the U.S. for treatment of unresectable/inoperable hypervascularized tumors.
Through the new partnership, Embol will be able to provide Ekobi microspheres to its ASC partners, according to a Feb. 21 press release.
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.
